DRGEM Valuation

Q: What is the Fair Price of A263690 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A263690 (₩5700) is trading above our estimate of [[fair value]] (₩3972.34)

Is A263690 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A263690 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A263690 (₩5700) is trading above our estimate of fair value (₩3972.34)

Significantly Below Fair Value: A263690 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A263690?

Key metric: As A263690 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A263690. This is calculated by dividing A263690's market cap by their current earnings.
What is A263690's PE Ratio?
PE Ratio	10x
Earnings	₩6.30b
Market Cap	₩62.79b

A263690 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.6x
Enterprise Value/EBITDA	6.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A263690's PE Ratio compare to its peers?

The above table shows the PE ratio for A263690 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	9.5x
A065510 Huvitz	6.8x	n/a	₩84.8b
A122310 Genoray	10x	n/a	₩76.9b
A041920 MEDIANALtd	13.2x	n/a	₩88.2b
A307280 Wonbiogen	8.1x	n/a	₩43.8b
A263690 DRGEM	10x	n/a	₩62.8b

Price-To-Earnings vs Peers: A263690 is expensive based on its Price-To-Earnings Ratio (10x) compared to the peer average (9.5x).

Price to Earnings Ratio vs Industry

How does A263690's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A035610 Solborn	2.5x	n/a	US$68.09m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A263690 is good value based on its Price-To-Earnings Ratio (10x) compared to the KR Medical Equipment industry average (12.5x).

Price to Earnings Ratio vs Fair Ratio

What is A263690's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A263690 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	10x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A263690's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Ray

₩100.3b

RAY Co., Ltd. provides x-ray diagnostic equipment in the dental industry.

A228670

₩6,470.00

-0.3%

-73.4%

Vieworks

₩200.2b

Develops, manufactures, and sells imaging systems and solutions.

A100120

₩21,800.00

6.3%

-19.1%

Boditech Med

₩347.2b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩15,800.00

0.1%

-10.4%